AstraZeneca Pharma India Q2 net profit dips 67% to Rs 9.13 cr

New Delhi: Drug firm AstraZeneca Pharma India Tuesday reported a 66.65 per cent dip in its net profit to Rs 9.13 crore for the quarter ended September 30, 2018. The company had posted a net profit of Rs 27.38 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a filing to BSE.

Company’s total revenue for the quarter under consideration stood at Rs 164.71 crore. It was Rs 166.75 crore for the same period year ago.

Shares of AstraZeneca Pharma India today closed at Rs 1,702.60 per scrip on BSE, up 0.70 per cent from the previous close.

  • Related Posts

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    Meerut: A four-year-old boy’s condition allegedly worsened after he was administered an anti-rabies injection at Sambhal district hospital following a snakebite. A pharmacist at the hospital has been removed from…

    Lupin gets tentative US FDA nod for apixaban oral suspension for patients who cannot swallow tablets

    Once final approval comes through, the liquid anticoagulant will be made at Lupin’s plant in Somerset, New Jersey, the company said. Mumbai: Lupin has received tentative approval from the US…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

    Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

    Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

    Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

    Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

    Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

    Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

    Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

    Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore

    Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore